EPOCH-F: A novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT

Bone Marrow Transplantation

Volumn 46, Issue 5, 2011, Pages 676-681

  Jamshed, S ^a   Fowler, D H ^b   Neelapu, S S ^c   Dean, R M ^d   Steinberg, S M ^b   Odom, J ^b   Bryant, K ^b   Hakim, F ^b   Bishop, M R ^b  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

allogeneic; multiple myeloma; reduced intensity; transplantation

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; DRUG SAFETY; ENGRAFTMENT; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PERICARDIAL EFFUSION; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SALVAGE THERAPY; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; PREDNISONE; SALVAGE THERAPY; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE; VINCRISTINE;

EID: 79955917256     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.173     Document Type: Article

References (32)

1. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007; 7: 585-598 (Pubitemid 47106630)
2. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al., InterGroupe Francophone du Myélome. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502 (erratum appears in N Engl J Med 2004; 350: 2628) (Pubitemid 38010075)
3. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021-1030 (Pubitemid 43357806)
4. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al., Assessment of proteasome inhibition for extending remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498
5. Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 2009; 114: 772-778
6. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood 1996; 87: 1196-1198 (Pubitemid 26043549)
7. Gahrton G, Svensson H, Cavo M, Apperly J, Bacigalupo A, Björkstrand B et al. European Group for Blood and Marrow Transplantation. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001; 113: 209-216 (Pubitemid 32423325)
8. Lokhorst HM, Schattenberg A, Cornelissen JJ, van Oers MH, Fibbe W, Russell I et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000; 18: 3031-3037 (Pubitemid 30648798)
9. Bellucci R, Wu CJ, Chiaretti S, Weller E, Davies FE, Alyea EP et al. Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood 2004; 103: 656-663 (Pubitemid 38140101)
10. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD et al. Standard chemotherapy compared with highdose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24: 929-936. (erratum appears in J Clin Oncol 2006; 24:2687) (Pubitemid 46638847)
11. Badros A, Barlogie B, Siegel E, Cottler-Fox M, Zangari M, Fassas A et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002; 20: 1295-1303 (Pubitemid 34177436)
12. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447-3454 (Pubitemid 37314788)
13. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007; 356: 1110-1120 (Pubitemid 46425595)
14. Lee CK, Badros A, Barlogie B, Morris C, Zangari M, Fassas A et al. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol 2003; 31: 73-80 (Pubitemid 36110532)
15. Peggs KS, Mackinnon S, Williams CD, D'Sa S, Thuraisundaram D, Kyriakou C et al. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Biol Blood Marrow Transplant 2003; 9: 257-265 (Pubitemid 40045612)
16. Kröger N, Perez-Simon JA, Myint H, Klingemann H, Shimoni A, Nagler A et al. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dosereduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2004; 10: 698-708 (Pubitemid 39272874)
17. Crawley C, Lalancette M, Szydlo R, Gilleece M, Peggs K, Mackinnon S et al. Chromic leukaemia working party of the EBMT. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 2005; 105: 4532-4539 (Pubitemid 40720805)
18. de Lavallade H, El-Cheikh J, Faucher C, Fürst S, Stoppa AM, Coso D et al. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma. Bone Marrow Transplant 2008; 41: 953-960 (Pubitemid 351850499)
19. Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 2002; 99: 2685-2693 (Pubitemid 34525353)
20. Bishop MR, Hou JW, Wilson WH, Steinberg SM, Odom J, Castro K et al. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas. Biol Blood Marrow Transplant 2003; 9: 162-169
21. Giles FJ, Wickham NR, Rapoport BL, Somlo G, Lim SW, Shan J et al. Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: an International Oncology Study Group (IOSG) phase II protocol. Am J Hematol 2000; 63: 125-130 (Pubitemid 30120765)
22. Björkstrand B, Rasmussen T, Remes K, Gruber A, Pelliniemi TT, Johnsen HE. Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma: a randomised phase II-study. Eur J Haematol 2003; 70: 379-383 (Pubitemid 36713933)
23. Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by highdose therapy and haemopoietic stem cell transplantation. Myeloma subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-1123 (Pubitemid 28435189)
24. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706 (Pubitemid 29126745)
25. Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 2002; 30: 367-373 (Pubitemid 35203509)
26. Kröger N, Sayer HG, Schwerdtfeger R, Kiehl M, Nagler A, Renges H et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002; 100: 3919-3924 (Pubitemid 35402053)
27. Mohty M, Boiron JM, Damaj G, Michallet AS, Bay JO, Faucher C et al. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 34: 77-84 (Pubitemid 39022961)
28. Crawley C, Iacobelli S, Björkstrand B, Apperley JF, Niederwieser D, Gahrton G. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007; 109: 3588-3594 (Pubitemid 46572554)
29. Keil F, Kalhs P, Chen X, Haas OA, Fritsch G, Chott A et al. Hematopoietic donor chimerism and graft-versus-myeloma effect in relapse of multiple myeloma after allogeneic bone marrow transplantation. Ann Hematol 1999; 78: 376-379 (Pubitemid 29419596)
30. Nencioni A, Schwarzenberg K, Brauer KM, Schmidt SM, Ballestrero A, Grünebach F et al. Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood 2006; 108: 551-558 (Pubitemid 44061355)
31. El-Cheikh J, Michallet M, Nagler A, de Lavallade H, Nicolini FE, Shimoni A et al. High response rate and improved graftversus- host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma. Haematologica 2008; 93: 455-458 (Pubitemid 351398650)
32. Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009; 113: 6069-6076